BIOTECH, STOCKS, TECHNOLOGY

John McCamant

Editor,

Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

Madrigal Pharmaceuticals (MDGL) has pitched a “perfect game” with their pristine MAESTRO-NASH Phase III trial for resmetirom hitting both primary, FDA agreed upon endpoints, asserts John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
Alaunos (TCRT) — my top speculative pick for 2023 — is a true next generation CAR-T cell therapy company focused on treating solid tumors, explains John McCamant, biotechnology specialist and editor of The Medical Technology Stock Letter.
Vaxart (VXRT) recently held their quarterly call and discussed their expected upcoming milestones including the selection of COVID-19 vaccine construct to be used in the UK human challenge study is expected in Q4 2022, reports John McCamant, editor of The Medical Technology Stock Letter.
Pacira Biosciences (PCRX) continues to deliver solid growth, notes John McCamant, a leading specialist in biotechnology stocks and editor of the Medical Technology Stock Letter.

John's Videos

John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.


John McCamant, editor of the Medical Technology Stock Letter, says he expects a bidding war for MYOV and important catalysts from MDGL, TCRT, and PGEN in Q4.

The Biotech indices have bounced 30% in 30 days (June 16-July 16) as over-sold conditions and biotech/drugs being immune to economic/recession fears have attracted new fund flows.



Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More